Skip to main content

Table 4 Analyses of complement activation markers in the subgroups of patients with systemic sclerosis

From: Analysis of complement biomarkers in systemic sclerosis indicates a distinct pattern in scleroderma renal crisis

 

n

C4d, mean (SD)

p value

C3bBbP, mean (SD)

p value

TCC, mean (SD)

p value

Sex

  

0.96

 

0.20

 

0.87

 Male

22

35.6 (40.3)

 

913 (574)

 

5.80 (3.69)

 

 Female

100

29.2 (18.3)

 

1119 (661)

 

8.39 (15.8)

 

Subset

  

0.88

 

0.11

 

0.36

 lcSSc

81

30.1 (25.2)

 

1143 (655)

 

8.56 (16.4)

 

 dcSSc

41

30.8 (20.7)

 

962 (629)

 

6.66 (9.34)

 

PAH

  

0.19

 

0.75

 

0.76

 No

96

31.8 (25.3)

 

1069 (645)

 

7.50 (12.4)

 

 Yes

26

25.0 (16.0)

 

1131 (676)

 

9.49 (20.5)

 

SRC

  

0.036

 

<0.001

 

0.003

 No

104

28.9 (23.7)

 

1156 (655)

 

8.57 (15.4)

 

 Yes

18

38.6 (22.9)

 

656 (423)

 

4.22 (5.54)

 

Ab

  

0.095

 

0.055

 

0.016

 ACA

34

30.7 (16.9)

 

1029 (594)

 

5.83 (5.70)

 

 ATA

22

32.7 (18.8)

 

1140 (744)

 

10.8 (22.0)

 

 ARA

17

35.0 (22.5)

 

761 (560)

 

3.19 (2.59)

 

 ANA+

40

29.5 (32.2)

 

1195 (642)

 

10.6 (18.0)

 

 ANA

9

18.1 (10.0)

 

1244 (705)

 

5.62 (3.36)

 

Pitting scar

  

0.50

 

0.35

 

0.76

 No

68

31.0 (26.1)

 

1071 (658)

 

9.30 (18.6)

 

 Yes

50

28.6 (19.0)

 

1155 (633)

 

6.53 (5.62)

 

Ulcer

  

0.35

 

0.36

 

0.54

 No

105

30.5 (23.9)

 

1090 (656)

 

8.31 (15.3)

 

 Yes

14

25.5 (17.8)

 

1183 (574)

 

6.19 (6.53)

 

Telangiectasias

  

0.83

 

0.19

 

0.39

 No

56

28.5 (17.8)

 

1003 (586)

 

6.07 (3.80)

 

 Yes

63

31.2 (27.2)

 

1189 (687)

 

9.84 (19.6)

 
  1. Abbreviations: PAH Pulmonary arterial hypertension, SRC Scleroderma renal crisis, Ab Autoantibodies, ACA Anti-centromere, ATA Anti-topoisomerase I, ARA Anti-RNA polymerase III, ANA + Anti-nuclear but not anti-centromere, anti-topoisomerase I or anti-RNA polymerase III, ANA No anti-nuclear autoantibodies, dcSSc Diffuse cutaneous systemic sclerosis, lcSSc Limited cutaneous systemic sclerosis, TCC Terminal complement complex
  2. Autoantibody analyses were by Kruskal-Wallis test; all others were by Mann-Whitney U test